Literature DB >> 9453605

Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes.

J K Pullen1, G W Anderson, S L Welkos, A M Friedlander.   

Abstract

The V protein expressed by pathogenic Yersinia pestis is an important virulence factor and protective immunogen. The presence of linear B-cell epitopes in the V protein was investigated by using a series of 17 overlapping linear peptides. Groups of 10 mice were immunized intraperitoneally with 30 microg of each peptide on days 0, 30, and 60. Although the V protein-specific antibody response to the peptides varied, most of the peptides elicited high antibody titers. The immunized mice were challenged subcutaneously with 60 50% lethal doses (LD50) (1 LD50 = 1.9 CFU) of a virulent Y. pestis strain, CO92. None of the peptide-immunized mice survived challenge. The animals immunized with the V protein were completely protected against challenge. The immunogenicity of some of the V peptides was increased by conjugating them to keyhole limpet hemocyanin. Only one peptide (encompassing amino acids 1 to 30) conjugate demonstrated some protection; the others were not protective. In additional experiments, V peptides that reacted well with sera from mice surviving Y. pestis infection were combined and used to immunize mice. Although the combined peptides appeared to be very immunogenic, they were not protective. Therefore, the protective B-lymphocyte epitope(s) in the V protein is most likely to be conformational.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453605      PMCID: PMC107937     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Evaluation of a microchip implant system used for animal identification in rats.

Authors:  D J Ball; G Argentieri; R Krause; M Lipinski; R L Robison; R E Stoll; G E Visscher
Journal:  Lab Anim Sci       Date:  1991-04

2.  Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.

Authors:  A Roggenkamp; A M Geiger; L Leitritz; A Kessler; J Heesemann
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

3.  Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides.

Authors:  P Chong; G Zobrist; C Sia; S Loosmore; M Klein
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

4.  The Yersinia pestis V antigen is a regulatory protein necessary for Ca2(+)-dependent growth and maximal expression of low-Ca2+ response virulence genes.

Authors:  S B Price; C Cowan; R D Perry; S C Straley
Journal:  J Bacteriol       Date:  1991-04       Impact factor: 3.490

5.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

6.  Detection of antigenic determinants in the Treponema pallidum membrane protein TmpA using overlapping synthetic peptides.

Authors:  G Antoni; G dal Maso; B Berti; C Soldatini; F Cocola
Journal:  J Immunol Methods       Date:  1996-01-16       Impact factor: 2.303

7.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

8.  Proteolysis of V antigen from Yersinia pestis.

Authors:  R R Brubaker; A K Sample; D Z Yu; R J Zahorchak; P C Hu; J M Fowler
Journal:  Microb Pathog       Date:  1987-01       Impact factor: 3.738

9.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

10.  Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine.

Authors:  L B Tabatabai; G W Pugh
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

View more
  9 in total

1.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

2.  Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis.

Authors:  Ho-Ki Shim; Julie A Musson; Helen M Harper; Hesta V McNeill; Nicola Walker; Helen Flick-Smith; Alexei von Delwig; E Diane Williamson; John H Robinson
Journal:  Immunology       Date:  2006-08-18       Impact factor: 7.397

3.  Amino acid and structural variability of Yersinia pestis LcrV protein.

Authors:  Andrey P Anisimov; Svetlana V Dentovskaya; Evgeniy A Panfertsev; Tat'yana E Svetoch; Pavel Kh Kopylov; Brent W Segelke; Adam Zemla; Maxim V Telepnev; Vladimir L Motin
Journal:  Infect Genet Evol       Date:  2009-10-14       Impact factor: 3.342

4.  LcrV plague vaccine with altered immunomodulatory properties.

Authors:  Katie A Overheim; R William Depaolo; Kristin L Debord; Elizabeth M Morrin; Debra M Anderson; Nathaniel M Green; Robert R Brubaker; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

6.  A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.

Authors:  Yashdeep Phanse; Brenda R Carrillo-Conde; Amanda E Ramer-Tait; Scott Broderick; Chang Sun Kong; Krishna Rajan; Ramon Flick; Robert B Mandell; Balaji Narasimhan; Michael J Wannemuehler
Journal:  Sci Rep       Date:  2014-01-20       Impact factor: 4.379

7.  Yersinia pestis Antigen F1 but Not LcrV Induced Humoral and Cellular Immune Responses in Humans Immunized with Live Plague Vaccine-Comparison of Immunoinformatic and Immunological Approaches.

Authors:  Valentina A Feodorova; Anna M Lyapina; Maria A Khizhnyakova; Sergey S Zaitsev; Yury V Saltykov; Vladimir L Motin
Journal:  Vaccines (Basel)       Date:  2020-11-19

8.  Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica.

Authors:  Wieslaw Swietnicki; Waldemar Goldeman; Mateusz Psurski; Anna Nasulewicz-Goldeman; Anna Boguszewska-Czubara; Marek Drab; Jordan Sycz; Tomasz M Goszczyński
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

9.  Benchmarking B-cell epitope prediction with quantitative dose-response data on antipeptide antibodies: towards novel pharmaceutical product development.

Authors:  Salvador Eugenio C Caoili
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.